Search Results

Your search for Jocelyn Solis-Moreira, MS matches 2 pages

Showing 1 - 2

By Jocelyn Solis-Moreira, MS / June 2021 / EHA 2021 Virtual Congress

Phase II Study of Naratuximab Emtansine Plus Rituximab in DLBCL

Adding the antibody-drug conjugate naratuximab emtansine to rituximab resulted in favorable overall survival and complete response rates for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), with a manageable safety profile. These findings from a phase II study were...

leukemia

lymphoma

By Jocelyn Solis-Moreira, MS / June 2021 / EHA 2021 Virtual Congress

Ibrutinib/Venetoclax vs Chlorambucil/Obinutuzumab in Previously Untreated Older Patients With CLL/SLL

In a primary analysis of the phase III GLOW study, a once-daily, all-oral, fixed-duration dose of ibrutinib and venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) resulted in superior progression-free survival than treatment with chlorambucil and obinutuzumab. Arnon...

Apr

Today In Oncology

Search Results

Your search for Jocelyn Solis-Moreira, MS matches 2 pages

Phase II Study of Naratuximab Emtansine Plus Rituximab in DLBCL

Ibrutinib/Venetoclax vs Chlorambucil/Obinutuzumab in Previously Untreated Older Patients With CLL/SLL

Adjuvant Pembrolizumab in Renal Cell Carcinoma: Overall Survival in KEYNOTE-564

Combined ICI and VEGF Inhibitor Trials in Cancer Cardiovascular Eligibility Criteria and Adverse Event Reporting

Risk of T-Cell and Second Primary Malignant Neoplasms After CAR T-Cell Therapy

Lack of Research Focused on Older Adults With Cancer May Be Contributing to Disparities in Care

Breast Cancer Survivors: Relationship Satisfaction and Emotional and Physical Well-Being